The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

January 20, 2025

Study Completion Date

January 20, 2025

Conditions

Acute Myocarditis

Interventions

DRUG

levosemindan

inotropic agent

Trial Locations (1)

Poison Control Center, Cairo

All Listed Sponsors

lead

Ain Shams University

OTHER

NCT06478667 - The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity | Biotech Hunter | Biotech Hunter